Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Friday, November 04, 2022
Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg booster dose of the companies’ Omicron BA.4/BA.5-...
read more
Wednesday, October 26, 2022
Codagenix, in collaboration with the Serum Institute of India, announced dosing has been initiated in an international, multi-center, randomized placebo-controlled Phase 3 clinical trial of CoviLiv.
read more
Sartorius entered a research partnership with The BASE Facility at The University of Queensland (UQ) to improve the manufacturing process of nucleic acid products led by the external collaboration ...
read more
Thursday, October 20, 2022
Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the FDA to provide a first booster dose at least six months after ...
read more
Wednesday, October 19, 2022
AstraZeneca's Evusheld™ (tixagevimab and cilgavimab), a long-acting antibody combination has received a Notice of Compliance from Health Canada for the treatment of mild to moderate COVID-19 in adults...
read more
Thursday, October 13, 2022
Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the afety, tolerability, and immunogenicity of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID...
read more
Thursday, October 13, 2022
The FDA amended the EUAs of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorize their use as a single booster dose in younger age groups.
read more
Tuesday, October 11, 2022
CSafe and BioLife Solutions, Inc. announced a new partnership to provide a combined global service network to support CGT products, with a focus on enhanced reliability, security and quality.
read more
Pfizer Canada and BioNTech announced that Health Canada authorized COMIRNATY Original & Omicron BA.4/BA.5 as a 30-µg booster dose for individuals ages 12 years and older.
read more
Saturday, October 01, 2022
Ahh – Steven King, the master of macabre. There was a time when I read all of his books.
I was particularly interested in his Dark Tower series of books. Taken from his website, stephenking.com:
read more
Thursday, September 22, 2022
A new study from Epic Research shows that the anti-viral treatment Paxlovid can meaningfully reduce COVID-19-related hospitalizations and deaths— even among patients under the age of 65. The rapid ...
read more
Wednesday, September 21, 2022
AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents (...
read more
Monday, September 19, 2022
Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) (...
read more
Friday, September 16, 2022
Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (...
read more
Tuesday, September 13, 2022
Pfizer Inc. and BioNTech SE announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 15/15 µg) has been recommended for ...
read more